Therapeutic development
Therapeutic Peptide Development — Discovery to Clinical Candidate
Peptides occupy a unique space in drug development — larger than small molecules, more accessible than biologics, and capable of engaging targets that neither can reach. Building a therapeutic peptide program requires integrating computational design, medicinal chemistry, and translational science. We support the full development arc from target to clinical candidate.
The Therapeutic Peptide Development Challenge
Therapeutic peptides face a distinctive set of development challenges: metabolic instability, limited oral bioavailability, potential immunogenicity, and manufacturing complexity. These challenges must be addressed systematically across the development arc — from initial candidate design through preclinical development.
Computational methods have transformed the early stages of peptide development — enabling more efficient candidate generation, property prediction, and optimization. But translating computational candidates into clinical-stage molecules requires integrating these methods with rigorous translational science.
Our Development Approach
Target-to-candidate design
Computational generation of candidate peptides optimized for target engagement and developability from the outset.
Iterative optimization
Systematic improvement of potency, selectivity, stability, and bioavailability through design-make-test-analyze cycles.
Translational readiness assessment
Evaluation of candidates against preclinical development criteria — PK, stability, formulation, and safety considerations.
Development pathway planning
Structured roadmap from lead candidate to IND-enabling studies, with clear go/no-go criteria at each stage.
Development Workflow
Target and program definition
Define therapeutic target, indication, and development objectives.
Discovery phase
AI-assisted candidate generation and initial property assessment.
Lead identification
Experimental validation and selection of lead candidates.
Lead optimization
Systematic optimization of potency, selectivity, stability, and PK properties.
Candidate selection
Selection of development candidate meeting predefined criteria.
Preclinical development
IND-enabling studies and regulatory preparation.
What Can Be Evaluated
What You May Receive
Development candidate
Optimized peptide candidate meeting predefined potency, selectivity, and developability criteria.
Preclinical data package
In vitro and in vivo data supporting IND filing and regulatory submission.
Development strategy document
Comprehensive roadmap from candidate to clinical stage.
IP landscape analysis
Assessment of freedom to operate and patentability for the development candidate.
Deliverables depend on program scope and therapeutic area. Clinical outcomes cannot be predicted or guaranteed.
Who This Is For
Biotech companies
Companies building peptide-based therapeutic pipelines and requiring integrated discovery and development support.
Pharmaceutical teams
Drug development teams exploring peptide modalities for targets where small molecules or biologics have limitations.
Academic spinouts
University spinout companies translating academic peptide discoveries into therapeutic development programs.
Frequently Asked Questions
Build a Therapeutic Peptide Development Program
Submit your target and therapeutic objectives. We will assess the development opportunity and outline a path from discovery to clinical candidate.
Confidential program discussions available under NDA.